Compositions and Methods for Treating Burns

Abstract

The present invention provides compositions and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof, and a pharmaceutically acceptable excipient.

Description

[0001]This application is a divisional of U.S. application Ser. No. 11 / 012,210, filed on Dec. 16, 2004, pending, which is hereby incorporated by reference herein in its entirety. This application also claims the benefit of International (PCT) Application No. PCT / US2004 / 031917, filed on Sep. 4, 2004, and U.S. Provisional Application No. 60 / 506,745, filed on Sep. 30, 2003, each of which is incorporated by reference herein in its entirety.FIELD OF THE INVENTION[0002]This invention relates generally to beneficial effects obtained via administration of a pharmaceutical composition for the treatment of burns and skin wounds in warm-blooded animals, such as mammals and especially humans. In particular, the present invention is concerned with inflammation-associated tissue damage and is particularly directed to prophylactic and therapeutic methods for treating localized and systemic inflammation associated with burns, as well as the treatment of a variety of diseases associated with the inf...

AI Technical Summary

Benefits of technology

[0024]The present invention also relates to a method for promoting rapid healing and / or regeneration of damaged tissues resulting from a burn comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof, and a pharmaceutically acceptable excipient, wherein said pharmaceutical composition promotes rapid healing and / or regeneration of damaged tissues while retaining the original composition of the tissue and minimizing complications and scarring associated with a burn.

[0025]The present invention also relates to a method for promoting rapid healing and / or regeneration of damaged tissues resulting from a burn comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising HR341g or a functional derivative thereof, and a pharmaceutically acceptable excipient, wherein said pharmaceutical composition promotes rapid healing and / or regeneration of damaged tissues while retaining the original composition of the tissue and minimizing complications and scarring associated with a burn.

[0026]In another aspect, the present invention also relates to a method for preventing or ameliorating the adverse affects associated with controlled thermal induced skin damage employed in scar and tattoo removal, cancer excisions, cautery excision of polyps, ulcers, treatment of decubitus ulcers (bedsores), acne, cutaneous fungal infections comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof, and a pharmaceutically acceptable excipient, wherein said pharmaceutical composition promotes rapid regeneration of damaged tissues while retaining the original composition of the tissue and minimizing complications and scarring associated with the thermally induced burn in one or more of the recited conditions.

[0030]In another aspect of the present invention, a method is provided for the use of a synthetic drug comprising an anti-cytokine or anti-inflammatory agent or functional derivative thereof to diminish pain or inflammation associated with a burn comprising blocking one or more components of the inflammatory pathway.

[0051]Either methodology inhibits the permeability of the microvasculature fluid, macromolecules, and blood cells thereby acting directly on the clinical edema and reducing the activation of detrimental metabolic cascades and pathways that require activation of the inflammatory pathway.

Problems solved by technology

Burns are the second leading cause of accidental death in the United States, with post burn care being traumatic, painful, lengthy and emotionally draining for the patient.

For example, drinking a very hot liquid or caustic substance such as acid can burn the esophagus and stomach.

Inhaling smoke or hot air from a fire in a burning building can burn the lungs.

When tissues are damaged by a burn, fluid may leak from blood vessels (capillary permeability), causing swelling or edema.

In an extensive burn, loss of a large amount of fluid from abnormally leaky blood vessels can cause shock.

In shock, blood pressure decreases so much that too little blood flows to the brain and other vital organs.

This type of burn, sometimes called an electrical arc burn, usually completely destroys and chars the skin at the current's point of entry into the body.

Most electrical burns also severely damage the tissues under the skin.

Large electrical shocks can paralyze breathing and disturb heart rhythm, causing dangerously irregular heartbeats.

Chemical burns can cause tissue death that can slowly spread for hours after the burn.

Radiation burns can cause inflammation, edema, ulcerations, damage to underlying endothelium and other cell types, as well as mutagenesis resulting in cancer, especially hematologic malignancies.

To date no one has produced a treatment capable of preventing the life threatening inflammatory response a burn victim can endure.

These include: an elevated venous hydrostatic pressure which may be caused by thrombosis of a vein or any other venous obstruction, heart failure; hypoproteinemia with reduced plasma oncotic pressure resulting from either inadequate synthesis or increased loss of albumin; increased osmotic pressure of the interstitial fluid due to abnormal accumulation of sodium in the body because renal excretion of sodium cannot keep pace with the intake; failure of the lymphatics to remove fluid and protein adequately from the interstitial space; an increased capillary permeability to fluids and proteins as occurs in the inflammatory response to tissue injury; and an increased mucopolysaccharide content within the interstitial spaces.

There are few, if any, agents that are therapeutically effective in the treatment of severe, local and systemic edemas.

Furthermore, as far as is known, there is no effective agent in present use as a prophylactic against these conditions.

The topical agents that are used to treat burns are limited.

However, none of these drugs stops edema.

Debridement and skin grafts in their present form, however, do not completely restore the function of healthy skin.

Furthermore, the grafted skin is prone to deformities such as hypertrophic scarring.

Currently it takes many months or even years to complete these extremely painful procedures.

Images